IC
CTMX icon

Innealta Capital’s CytomX Therapeutics CTMX Stock Holding History

Innealta Capital’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2
Closed -$2 – 511
2024
Q2 		$2 Buy
+2
New +$4 ﹤0.01% 1836

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Innealta Capital's CTMX Position: Q3 2024 in Review

Innealta Capital sold out of CytomX Therapeutics (CTMX) in Q3 2024, closing a stake of 2 shares — an estimated $2 sold.

Innealta Capital first reported a position in CTMX in Q2 2024 and held it in 1 quarter. The position peaked at $2 in Q2 2024. 69 funds tracked by Wall St. Rank hold CTMX as of Q3 2024.

  • Innealta Capital reported no remaining CytomX Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Innealta Capital sold 2 CytomX Therapeutics shares in Q3 2024, an estimated $2.
  • Innealta Capital first reported a position in CytomX Therapeutics in Q2 2024 and held it in 1 quarter.
  • Innealta Capital's CytomX Therapeutics position peaked at $2 in Q2 2024.
  • 69 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2024.

Based on Innealta Capital's 13F filing for Q3 2024, filed 29 Oct 2024.